The GEOMETRY mono-1 study showed an overall response rate (ORR) of 72.0% (95% CI: 50.6-87.9) in treatment-naive patients and 39.1% (95% CI: 27.6-51.6) in previously treated patients. ORR
The post Phase II trial of capmatinib demonstrates positive results in NSCLC appeared first on Pharma Business review.
Original Article: Phase II trial of capmatinib demonstrates positive results in NSCLC